Progression of $\textit{TP53}$-Mutant Clonal Hematopoiesis into Therapy-Related B-Cell Acute Lymphoblastic Leukemia
Year: 2026
Type: dissertation
Abstract: Clonal hematopoiesis (CH) is an age-associated condition in which hematopoietic stem and progenitor cells (HSPCs) acquire somatic mutations in leukemia driver genes that confer a competitive growth advantage, resulting in the expansion of mutant blood cell clones. Among the genes most frequently affected is TP53 (termed Trp53 in mice), a key tumor suppressor whose mutations are strongly associated with therapy-related myeloid malignancies. Previous clinical and experimental studies have established that TP53-mutant CH can serve as a reservoir for therapy-related acute myeloid leukemia (t-AML), where cytotoxic chemotherapy or radiation therapy selectively promotes the expansion of pre- existing TP53-mutant HSPCs. Whether a similar mechanism contributes to the development of therapy-related B-cell acute lymphoblastic leukemia (B-ALL) has remained unknown. Recent genomic studies have identified TP53 and other CH-associated mutations in patients with therapy-related and low-hypodiploid (LH)- B-ALL, suggesting that TP53-mutant CH may also represent a precursor state for lymphoid malignancies. However, these observations were based on retrospective patient cohorts and therefore could not establish a causal relationship between CH and B-ALL development. The aim of this thesis was to determine experimentally whether TP53-mutant CH can progress into therapy-related B-ALL. To address this question, a conditional murine model of TP53- mutant CH was developed in which mutant HSPCs were exposed to genotoxic stress through γ-irradiation, mimicking the selective pressure of anti-cancer therapy. This approach resulted in the expansion of Trp53-mutant HSPCs, including lymphoid progenitors, and led to the development of B-ALL in approximately 30% of mice. The resulting leukemias were transplantable into non-conditioned immunocompetent recipients, where they faithfully recapitulated the immunophenotypic and pathological characteristics of the primary disease. Biallelic Trp53 inactivation was required for malignant transformation. Whole-genome sequencing (WGS) revealed extensive chromosomal losses and complex copy-number alterations (CNAs) closely resembling those observed in human TP53-mutant B-ALL. Furthermore, transcriptomic analyses showed that murine Trp53-mutant B-ALL closely resembled the transcriptional profiles of human B-ALL, supporting the biological relevance of the model. Collectively, this work provides the first prospective experimental evidence that TP53-mutant CH can serve as a precursor of therapy-related B-ALL. These findings extend the role of CH beyond myeloid malignancies, establish a mechanistic link between pre-existing TP53-mutant HSPCs and lymphoid leukemogenesis following genotoxic stress, and provide a robust preclinical model for investigating disease biology and developing novel therapeutic strategies for this high-risk subtype of B-ALL.
DOI: 10.5167/uzh-437303
Author: Topcu, Ebru
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7225891735
